Taofeek K Owonikoko
Overview
Explore the profile of Taofeek K Owonikoko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
192
Citations
7671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang G, Pannucci A, Ivanov A, Switchenko J, Sun S, Sica G, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941812
To investigate the preclinical efficacy and identify predictive biomarkers of polo-like kinase 1 (PLK1) inhibitors in small cell lung cancer (SCLC) models. We tested the cytotoxicity of selective PLK1 inhibitors...
2.
Sands J, Champiat S, Hummel H, Paulson K, Borghaei H, Alvarez J, et al.
Cancer
. 2025 Jan;
131(3):e35738.
PMID: 39876075
Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients...
3.
Mahalingam D, Owonikoko T, Delpassand E, Mulcahy M, Kalyan A, Ulahannan S, et al.
Cancer
. 2025 Jan;
131(1):e35680.
PMID: 39748726
Background: Yttrium-90 FF-21101 (Y-FF-21101) is a radiopharmaceutical that targets P-cadherin as a therapy against solid tumors. A previously reported, first-in-human study determined that a dose of 25 mCi/m was safe,...
4.
Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M, et al.
Future Oncol
. 2024 Nov;
20(40):3355-3364.
PMID: 39530627
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was...
5.
Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, et al.
JCO Oncol Pract
. 2024 Oct;
21(3):292-299.
PMID: 39374449
Purpose: International medical graduates (IMGs) are an essential component of the oncology workforce in the United States, comprising a third of all practicing oncologists and almost half of hematology/oncology fellows....
6.
7.
Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M, et al.
N Engl J Med
. 2023 Oct;
389(22):2063-2075.
PMID: 37861218
Background: Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer....
8.
Lalonde C, Switchenko J, Behera M, Bilen M, Owonikoko T, Kaufman J, et al.
Oncologist
. 2023 Jul;
28(12):1055-1063.
PMID: 37418599
Racial and ethnic minority populations are consistently under-represented in oncology clinical trials despite comprising a disproportionate share of a cancer burden. Phase I oncology clinical trials pose a unique challenge...
9.
Chattaraj A, Syed M, Low C, Owonikoko T
JCO Oncol Pract
. 2023 Mar;
19(5):278-283.
PMID: 36921239
Cisplatin is a bedrock of cancer management and one of the most used chemotherapeutic agents in the treatment of germ cell, lung, bladder, ovarian, and head and neck cancers. Approximately...
10.
Paz-Ares L, Champiat S, Lai W, Izumi H, Govindan R, Boyer M, et al.
J Clin Oncol
. 2023 Jan;
41(16):2893-2903.
PMID: 36689692
Purpose: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule,...